ChemicalBook >> journal list >> Advanced Science >>article
Advanced Science

Advanced Science

IF: 14.3
Download PDF

HSPA8 Activates Wnt/β-Catenin Signaling to Facilitate BRAF V600E Colorectal Cancer Progression by CMA-Mediated CAV1 Degradation.

Published:16 November 2023 DOI: 10.1002/advs.202306535 PMID: 37973552
Bowen Li, Hui Ming, Siyuan Qin, Li Zhou, Zhao Huang, Ping Jin, Liyuan Peng, Maochao Luo, Tingting Zhang, Kui Wang, Rui Liu, Yih-Cherng Liou, Edouard C. Nice, Jingwen Jiang, Canhua Huang

Abstract

BRAF V600E attracts wide attention in the treatment of colorectal cancer (CRC) as stratifying and predicting a refractory classification of CRC. Recent evidence indicates that Wnt/β-catenin signaling is broadly activated and participates in the refractoriness of BRAF V600E CRC, but the underlying molecular mechanism needs to be elucidated. Here, heat shock 70 kDa protein 8 (HSPA8), an essential regulator in chaperone-mediated autophagy (CMA), is identified as a potential therapeutic target for advanced BRAF V600E CRC. These results show that HSPA8 is transcriptionally upregulated in BRAF V600E CRC, which promotes CMA-dependent degradation of caveolin-1 (CAV1) to release β-catenin into the nucleus and thus activates the Wnt/β-catenin pathway, contributing to metastasis and progression of BRAF V600E CRC. Of note, HSPA8 directly interacts with the KIFSN motif on CAV1, the interaction can be enhanced by p38 MAPK-mediated CAV1 S168 phosphorylation. Furthermore, pharmacological targeting HSPA8 by VER155008 exhibits synergistic effects with BRAF inhibitors on CRC mouse models. In summary, these findings discover the important role of the HSPA8/CAV1/β-catenin axis in the development of refractory BRAF V600E CRC and highlight HSPA8 as a predictive biomarker and therapeutic target in clinical practice.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Encorafenib (LGX818) 1269440-17-6 C22H27ClFN7O4S 174 suppliers $37.00-$5210.50
Encorafenib (LGX818) 1269440-17-6 C22H27ClFN7O4S 174 suppliers $37.00-$5210.50
Encorafenib (LGX818) 1269440-17-6 C22H27ClFN7O4S 174 suppliers $37.00-$5210.50
Encorafenib (LGX818) 1269440-17-6 C22H27ClFN7O4S 174 suppliers $37.00-$5210.50

Similar articles